Navigation Links
Synosia Therapeutics Announces Appointment of Chief Business Officer
Date:12/13/2007

SAN FRANCISCO, December 13 /PRNewswire/ -- Synosia Therapeutics today announced the appointment of Antony Blanc, Ph.D., as the company's new chief business officer, effective immediately.

Dr Blanc, who will serve as head of Synosia's office in Basel, Switzerland, joins from Syngenta, where he created and led the biopharmaceuticals business unit. A molecular biologist by training and an experienced biotech entrepreneur, Dr. Blanc helped biotech and pharma clients with R&D, commercial and strategy issues as associate partner with the business consultants McKinsey & Company.

"With a strong entrepreneurial flair in biotech and expertise in both science and business, Antony Blanc brings together the skills we need to lead our increasingly important presence in Switzerland," said Synosia Chief Executive Officer and President Dr. Ian Massey. "Our three pharmaceutical partners are based in Basel and this appointment will give us the leadership we need in Europe to meet our ambitious goals for 2008, including the start of four phase II trials."

"Synosia has a broad clinical-stage portfolio with several advanced molecules, highly experienced leaders, a well-aligned and strong investor base and a grounding in both the US and in Switzerland. I look forward to building on this promising combination to create a leading CNS-focused specialty pharma company" said Blanc.

Antony Blanc replaces Herve Girsault M.B.A., who will remain on Synosia's board of directors and continue to act as a key business advisor to the company.

About Synosia Therapeutics

Synosia Therapeutics develops and intends to commercialize innovative and clinically differentiated products for unmet medical needs in psychiatry and neurology. The privately-owned company is developing six clinical-stage compounds acquired through key partnerships with Novartis, Roche and Syngenta, including two marketed drugs that will be tested in new indications, extending their reach
'/>"/>

SOURCE Synosia Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... Mich., March 26, 2015 Neogen Corporation (NASDAQ: ... for the third quarter of fiscal 2015, which ended ... the prior year,s $6,575,000. Earnings per share in the ... ago. Current year-to-date net income increased 17% over prior ... $20,621,000, or $0.56 per share, for the same period ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 "In America," the ... the United States that is hosted by legendary film actor ... topic of botany in an upcoming segment. , Botany ... in reality it is actually quite a bit more complicated ... of different types of living organisms, from the smallest bacteria ...
(Date:3/25/2015)... of the most attractive in the emerging European region, ... economy and increasing government investment in healthcare, according to ... is set to grow at twice the pace of ... annually reaching an approximate market value of $43-60 billion ... Green Cross provides total healthcare solutions that address the ...
(Date:3/25/2015)... , March 25, 2015 Optimal Research, ... Vaccine Industry Excellence (ViE) Award "Best Clinical Site or ... year that Optimal has been selected as a nominee ... Congress, receiving a "Highly Recommended" distinction in 2014. The ... of the efforts, accomplishments, and positive contributions of companies ...
Breaking Biology Technology:Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2
... FRANCISCO, Calif., May 15 Poniard Pharmaceuticals, Inc. (Nasdaq: ... oncology, today announced that it has filed a shelf ... Exchange Commission (SEC) that, when declared effective by the ... offer and sell up to $60 million aggregate amount ...
... DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or ... financial results for the first quarter of 2009. DOR,s ... $0.5 million compared to $0.7 million for the first ... attributable to decreased research and development amounts drawn down ...
... -- Tiens Biotech Group (USA), Inc. (the,"Company" or "Tiens", NYSE ... financial results for the first quarter ended March 31, 2009. ... of 2009 increased 42% to $18.2 million,compared to $12.8 million ... international sales. , Net income attributable ...
Cached Biology Technology:Poniard Pharmaceuticals Files Shelf Registration 2Poniard Pharmaceuticals Files Shelf Registration 3DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 5Tiens Biotech Group (USA) Reports First Quarter Results 2Tiens Biotech Group (USA) Reports First Quarter Results 3Tiens Biotech Group (USA) Reports First Quarter Results 4Tiens Biotech Group (USA) Reports First Quarter Results 5Tiens Biotech Group (USA) Reports First Quarter Results 6Tiens Biotech Group (USA) Reports First Quarter Results 7Tiens Biotech Group (USA) Reports First Quarter Results 8Tiens Biotech Group (USA) Reports First Quarter Results 9Tiens Biotech Group (USA) Reports First Quarter Results 10Tiens Biotech Group (USA) Reports First Quarter Results 11
(Date:3/11/2015)... 11, 2015   The Sync Project™ ... scientifically measure and harness music to improve health. ... and objective measurements of physiology, enabling the study ... in large populations. It is designed for medical ... perform rigorous studies and accelerate the discovery of ...
(Date:3/10/2015)... 10, 2015 Transforming How We ... "Personalized Medicine in Human Space Flight" by ... Goodwin , Ph.D. was recently featured by Springer Science ... years. Specifically, "Personalized Medicine in Human Space ... published in 2013 and 2014 from Springer in the ...
(Date:3/10/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce ... been named the "Number One Best Tech Gift ... Modern ( http://www.rethinkmodern.com/ ) is a web magazine focused ... that have a unique function or design.  ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4
... UN report provides definitive answers and ways to repair lives ... eventually die of radiation exposure from the Chernobyl nuclear power ... of more than 100 scientists has concluded. , As of ... to radiation from the disaster, almost all being highly exposed ...
... September the chlorophyll starts to disappear from the leaves of plants. ... the explosion of colors we now have in store. A research ... protein that helps bring out the color splendor of plants in ... in the scientific journal PNAS, Proceedings of the National Academy ...
... Using sunlight to power our homes and offices is an ... better use of solar energy. The study of photosynthesis in ... almost 100% of the sun-light reaching them, and how they ... Haumann and Holger Dau, from the Freie Universit├Ąt Berlin, used ...
Cached Biology News:Chernobyl: The true scale of the accident 2Chernobyl: The true scale of the accident 3Chernobyl: The true scale of the accident 4Chernobyl: The true scale of the accident 5Chernobyl: The true scale of the accident 6Chernobyl: The true scale of the accident 7Chernobyl: The true scale of the accident 8Chernobyl: The true scale of the accident 9Chernobyl: The true scale of the accident 10Chernobyl: The true scale of the accident 11Chernobyl: The true scale of the accident 12Chernobyl: The true scale of the accident 13Chernobyl: The true scale of the accident 14Chernobyl: The true scale of the accident 15Chernobyl: The true scale of the accident 16Protein behind autumn color splendor identified 2Plants reveal a secret and bring researchers nearer a cleaner future 2
Moue Serum 8-12 Weeks Old...
...
... There are at least 20 structurally and ... the TGF-beta superfamily. BMPs were originally identified ... formation. They are also involved in embryogenesis ... BMPs regulate the growth, differentiation, chemotaxis and ...
MOUSE ANTI HUMAN NPM...
Biology Products: